ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
What is Erytech Pharma Sa's quote symbol?
What is the 52 week high and low for Erytech Pharma Sa (NASDAQ: ERYP)?
How much is Erytech Pharma Sa stock worth today?
How much is Erytech Pharma Sa's stock price per share?
What is Erytech Pharma Sa's Market Cap?